

# Richard E K Russell

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4258597/publications.pdf>

Version: 2024-02-01

52  
papers

2,990  
citations

430843  
18  
h-index

276858  
41  
g-index

56  
all docs

56  
docs citations

56  
times ranked

3611  
citing authors

#	ARTICLE	IF	CITATIONS
1	Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis. Lancet Respiratory Medicine,the, 2022, 10, 545-556.	10.7	30
2	Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine,the, 2021, 9, 763-772.	10.7	301
3	Predicting treatment outcomes following an exacerbation of airways disease. PLoS ONE, 2021, 16, e0254425.	2.5	3
4	Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet, The, 2021, 398, 843-855.	13.7	204
5	Renaming COPD exacerbations: the UK respiratory nursing perspective. BMC Pulmonary Medicine, 2021, 21, 299.	2.0	2
6	A new piece in the puzzle: the eosinophil and the development of COPD. European Respiratory Journal, 2021, 58, 2101105.	6.7	4
7	30-day Readmission After an Acute Exacerbation of Chronic Obstructive Pulmonary Disease is Associated with Cardiovascular Comorbidity. , 2021, 22, 369-375.		2
8	Discordant diagnostic criteria for pneumonia in COPD trials: a review. European Respiratory Review, 2021, 30, 210124.	7.1	8
9	In the race at last: post-hoc analysis of GALATHEA and TERRANOVA. Lancet Respiratory Medicine,the, 2020, 8, 127-129.	10.7	1
10	Exacerbations of chronic obstructive pulmonary disease: time to rename. Lancet Respiratory Medicine,the, 2020, 8, 133-135.	10.7	13
11	Finding the true prevalence of obstructive lung disease: two steps forward and one step back. European Respiratory Journal, 2020, 55, 2001514.	6.7	1
12	<p>Covid-19 and COPD: A Personal Reflection</p>. International Journal of COPD, 2020, Volume 15, 883-884.	2.3	5
13	Evaluating the sensitivity and specificity of NEATstik technology compared to an activity-based immunoassay in sputum samples from participants with COPD. European Respiratory Journal, 2020, 55, 1902412.	6.7	0
14	&lt;p&gt;The acute wheezy adult with airways disease in the emergency department: a retrospective case-note review of exacerbations of COPD&lt;/p&gt;. International Journal of COPD, 2019, Volume 14, 971-977.	2.3	8
15	<p>â€œBreathing New Life Into Chronic Obstructive Pulmonary Disease (COPD)â€ Results From An Online Survey Of UK Patients</p>. International Journal of COPD, 2019, Volume 14, 2799-2807.	2.3	3
16	The Use of Inhaled Corticosteroids to Prevent Acute Exacerbations of COPD: A Pro/Con Debate. Turkish Thoracic Journal, 2019, 20, 198-202.	0.6	0
17	What will Happen in the World of COPD 2030?. Turkish Thoracic Journal, 2019, 20, 153-257.	0.6	0
18	What Does the TOVITO Programme Tell Us about How We Can Manage COPD?. Turkish Thoracic Journal, 2018, 19, 216-219.	0.6	3

#	ARTICLE	IF	CITATIONS
19	Toward effective prescription of inhaled corticosteroids in chronic airway disease. International Journal of COPD, 2018, Volume 13, 3419-3424.	2.3	2
20	Investigating blood eosinophil count thresholds in patients with COPD. Lancet Respiratory Medicine, 2018, 6, 823-824.	10.7	5
21	Why choose tiotropium for my patient? A comprehensive review of actions and outcomes versus other bronchodilators. Respiratory Medicine, 2017, 128, 28-41.	2.9	15
22	Eosinophils in COPD: just another biomarker?. Lancet Respiratory Medicine, 2017, 5, 747-759.	10.7	160
23	Comparison of the peripheral blood eosinophil count using near-patient testing and standard automated laboratory measurement in healthy, asthmatic and COPD subjects. International Journal of COPD, 2017, Volume 12, 2771-2775.	2.3	9
24	Are COPD and cardiovascular disease fundamentally intertwined?. European Respiratory Journal, 2016, 47, 1307-1309.	6.7	6
25	Enhanced monocyte migration to CXCR3 and CCR5 chemokines in COPD. European Respiratory Journal, 2016, 47, 1093-1102.	6.7	53
26	Metabolic Effects Associated with ICS in Patients with COPD and Comorbid Type 2 Diabetes: A Historical Matched Cohort Study. PLoS ONE, 2016, 11, e0162903.	2.5	43
27	Chronic obstructive pulmonary disease. Current Opinion in Pulmonary Medicine, 2014, 20, 127-131.	2.6	7
28	Children must be protected from the tobacco industry's marketing tactics. BMJ, The, 2013, 347, f7358-f7358.	6.0	2
29	Management of acute asthma in the UK: Table 1. Emergency Medicine Journal, 2013, 30, 864.2-864.	1.0	0
30	Management Strategies. , 2013, , 43-57.		0
31	The Future of COPD. , 2013, , 77-92.		0
32	Expression of muscarinic receptors by human macrophages. European Respiratory Journal, 2012, 39, 698-704.	6.7	53
33	Optimizing management of chronic obstructive pulmonary disease in the upcoming decade. International Journal of COPD, 2011, 6, 47.	2.3	8
34	The Future of COPD. , 2011, , 75-90.		1
35	Treatment Effects of Low-Dose Theophylline Combined With an Inhaled Corticosteroid in COPD. Chest, 2010, 137, 1338-1344.	0.8	166
36	Setting the standard for routine asthma consultations: a discussion of the aims, process and outcomes of reviewing people with asthma in primary care. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2010, 19, 75-83.	2.3	42

#	ARTICLE	IF	CITATIONS
37	Noninvasive ventilation: has Pandora's box been opened?. International Journal of COPD, 2010, 5, 55.	2.3	4
38	Expression of Transient Receptor Potential C6 Channels in Human Lung Macrophages. American Journal of Respiratory Cell and Molecular Biology, 2010, 43, 296-304.	2.9	55
39	ICS and COPD: Time to clear the air. International Journal of COPD, 2009, 4, 289.	2.3	3
40	Impact factor and its role in academic promotion. International Journal of COPD, 2009, 4, 265.	2.3	7
41	Leukotriene B4 release by human lung macrophages via receptor- not voltage-operated Ca <sup>2+</sup> channels. European Respiratory Journal, 2009, 33, 1105-1112.	6.7	11
42	Management of Exacerbation of COPD. Acute Medicine, 2008, 7, 21-7.	0.3	0
43	The Role of IÎB Kinase 2, but Not Activation of NF-ÎB, in the Release of CXCR3 Ligands from IFN-Î3-Stimulated Human Bronchial Epithelial Cells. Journal of Immunology, 2007, 179, 6237-6245.	0.8	43
44	Which bronchodilator in COPD?. International Journal of COPD, 2007, 2, 93-4.	2.3	0
45	The big picture and the little picture. International Journal of COPD, 2006, 1, 97-97.	2.3	0
46	Anti-inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2004, 287, L774-L783.	2.9	297
47	Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD. Thorax, 2003, 58, 942-946.	5.6	185
48	Impaired Inhibition by Dexamethasone of Cytokine Release by Alveolar Macrophages from Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 24-31.	5.6	281
49	Matrix Metalloproteinase-9 Expression in Asthma. Chest, 2002, 122, 1543-1552.	0.8	162
50	Alveolar macrophage-mediated elastolysis: roles of matrix metalloproteinases, cysteine, and serine proteases. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2002, 283, L867-L873.	2.9	208
51	Release and Activity of Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 by Alveolar Macrophages from Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory Cell and Molecular Biology, 2002, 26, 602-609.	2.9	386
52	Effect of Theophylline on Induced Sputum Inflammatory Indices and Neutrophil Chemotaxis in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 1371-1376.	5.6	163